243 research outputs found
Dyspnoea, wheezing and respiratory insufficiency in pregnancy: Was it bronchial or cardiac astha?
SCOPUS: ed.jinfo:eu-repo/semantics/publishe
Chest physical examination: A new series of review papers
SCOPUS: ed.jinfo:eu-repo/semantics/publishe
The birth and development of the forced expiratory manoeuvre: A tribute to Robert Tiffeneau (1910-1961)
SCOPUS: re.jinfo:eu-repo/semantics/publishe
Que penser des corticoïdes en aérosol doseur ?
SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Corticoïdes et bronchopneumopathies chroniques obstructives
SCOPUS: re.jinfo:eu-repo/semantics/publishe
Mechanical assistance in chronic respiratory insufficiency due to neuromuscular disease
It is now quite clear that patients with chronic respiratory failure due to neuromuscular disorders may be helped by night-time ventilation at home, or for some of them by diaphragm pacing. Their quality of life will be markedly improved as soon as the chronic hypercapnia disappears, although the mechanism for this disappearance remains incompletely understood. However, we have to face many ethical as well as practical problems to ensure these patients and their families a safe transition from the hospital to home care, requiring concerted interdisciplinary efforts.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
LES BRONCHODILATATEURS ENDOBRONCHIQUES
There are two families of inhaled bronchodilators: β-2-mimetics and vagolytics. They are equally effective in patients with chronic obstructive pulmonary disease (COPD), whereas β-mimetics are usually superior in asthmatics. The clinical benefits linked to long acting β-mimetics like salmeterol are already established in asthmatics. Metered dose aerosols remain the most widely used type of inhaler, eventually connected to a spacer, together with powder inhalers. Usual bronchodilators are now prescribed on demand rather than on a regular basis. There is no proof that β-mimetics are causally related to asthma deaths. Inhaled corticosteroids, which have no acute bronchospasmolytic properties, are the first-choice chronic drug treatment of moderate to severe asthma; they are currently being evaluated in COPD.SCOPUS: sh.jinfo:eu-repo/semantics/publishe
- …